@article{wassef_adalimumab_2012,
	title = {Adalimumab for the treatment of pityriasis rubra pilaris: a case report},
	volume = {90},
	copyright = {All rights reserved},
	issn = {0011-4162 (Print) 0011-4162 (Linking)},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/23270195},
	abstract = {Pityriasis rubra pilaris (PRP) is a chronic papulosquamous eruption of the skin characterized by follicular hyperkeratosis, salmon pink scaly plaques with islands of unaffected skin, and palmoplantar keratoderma. Widely used oral systemic and topical treatments are not greatly effective. We present a 62-year-old man with PRP of 2 years' duration who used routine topical treatments, oral retinoids, and UV therapy without improvement, but his symptoms greatly improved with the initiation of adalimumab.},
	number = {5},
	journal = {Cutis},
	author = {Wassef, C. and Lombardi, A. and Rao, B. K.},
	month = nov,
	year = {2012},
	keywords = {Adalimumab, Anti-Inflammatory Agents/*administration \& dosage, Antibodies, Monoclonal, Humanized/*administration \& dosage/*therapeutic use, Humans, Injections, Subcutaneous, Male, Middle Aged, Pityriasis Rubra Pilaris/*drug therapy/*pathology},
	pages = {244--7},
}

{"_id":"RoHevyDF7rv6PoeYC","bibbaseid":"wassef-lombardi-rao-adalimumabforthetreatmentofpityriasisrubrapilarisacasereport-2012","author_short":["Wassef, C.","Lombardi, A.","Rao, B. K."],"bibdata":{"bibtype":"article","type":"article","title":"Adalimumab for the treatment of pityriasis rubra pilaris: a case report","volume":"90","copyright":"All rights reserved","issn":"0011-4162 (Print) 0011-4162 (Linking)","url":"https://www.ncbi.nlm.nih.gov/pubmed/23270195","abstract":"Pityriasis rubra pilaris (PRP) is a chronic papulosquamous eruption of the skin characterized by follicular hyperkeratosis, salmon pink scaly plaques with islands of unaffected skin, and palmoplantar keratoderma. Widely used oral systemic and topical treatments are not greatly effective. We present a 62-year-old man with PRP of 2 years' duration who used routine topical treatments, oral retinoids, and UV therapy without improvement, but his symptoms greatly improved with the initiation of adalimumab.","number":"5","journal":"Cutis","author":[{"propositions":[],"lastnames":["Wassef"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Lombardi"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Rao"],"firstnames":["B.","K."],"suffixes":[]}],"month":"November","year":"2012","keywords":"Adalimumab, Anti-Inflammatory Agents/*administration & dosage, Antibodies, Monoclonal, Humanized/*administration & dosage/*therapeutic use, Humans, Injections, Subcutaneous, Male, Middle Aged, Pityriasis Rubra Pilaris/*drug therapy/*pathology","pages":"244–7","bibtex":"@article{wassef_adalimumab_2012,\n\ttitle = {Adalimumab for the treatment of pityriasis rubra pilaris: a case report},\n\tvolume = {90},\n\tcopyright = {All rights reserved},\n\tissn = {0011-4162 (Print) 0011-4162 (Linking)},\n\turl = {https://www.ncbi.nlm.nih.gov/pubmed/23270195},\n\tabstract = {Pityriasis rubra pilaris (PRP) is a chronic papulosquamous eruption of the skin characterized by follicular hyperkeratosis, salmon pink scaly plaques with islands of unaffected skin, and palmoplantar keratoderma. Widely used oral systemic and topical treatments are not greatly effective. We present a 62-year-old man with PRP of 2 years' duration who used routine topical treatments, oral retinoids, and UV therapy without improvement, but his symptoms greatly improved with the initiation of adalimumab.},\n\tnumber = {5},\n\tjournal = {Cutis},\n\tauthor = {Wassef, C. and Lombardi, A. and Rao, B. K.},\n\tmonth = nov,\n\tyear = {2012},\n\tkeywords = {Adalimumab, Anti-Inflammatory Agents/*administration \\& dosage, Antibodies, Monoclonal, Humanized/*administration \\& dosage/*therapeutic use, Humans, Injections, Subcutaneous, Male, Middle Aged, Pityriasis Rubra Pilaris/*drug therapy/*pathology},\n\tpages = {244--7},\n}\n\n\n\n","author_short":["Wassef, C.","Lombardi, A.","Rao, B. K."],"key":"wassef_adalimumab_2012","id":"wassef_adalimumab_2012","bibbaseid":"wassef-lombardi-rao-adalimumabforthetreatmentofpityriasisrubrapilarisacasereport-2012","role":"author","urls":{"Paper":"https://www.ncbi.nlm.nih.gov/pubmed/23270195"},"keyword":["Adalimumab","Anti-Inflammatory Agents/*administration & dosage","Antibodies","Monoclonal","Humanized/*administration & dosage/*therapeutic use","Humans","Injections","Subcutaneous","Male","Middle Aged","Pityriasis Rubra Pilaris/*drug therapy/*pathology"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/raoresearch","dataSources":["aGgndugSyribdb2rd","2tgmyzKov4y6MHvQs"],"keywords":["adalimumab","anti-inflammatory agents/*administration & dosage","antibodies","monoclonal","humanized/*administration & dosage/*therapeutic use","humans","injections","subcutaneous","male","middle aged","pityriasis rubra pilaris/*drug therapy/*pathology"],"search_terms":["adalimumab","treatment","pityriasis","rubra","pilaris","case","report","wassef","lombardi","rao"],"title":"Adalimumab for the treatment of pityriasis rubra pilaris: a case report","year":2012}